Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma

Oncogene

Volumn 34, Issue 29, 2015, Pages 3770-3779

  Brun, S N ^a,b,c   Markant, S L ^a,b,c   Esparza, L A ^a,b   Garcia, G ^d   Terry, D ^e   Huang, J M ^f   Pavlyukov, M S ^g,h   Li, X N ⁱ   Grant, G A ^j   Crawford, J R ^k,l,m   Levy, M L ^m,n   Conway, E M ^o   Smith, L H ^a,e   Nakano, I ^g,h   Berezov, A ^f   Greene, M I ^p   Wang, Q ^f   Wechsler Reya, R J ^a,b,c  

^a BURNHAM INSTITUTE   (United States)

^b SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Histopathology Core SBMRI   (United States)

^e Conrad Prebys Center for Chemical Genomics SBMRI ^*  (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

^j STANFORD UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m RADY CHILDREN'S HOSPITAL   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^p UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN PATCHED; SEPANTRONIUM BROMIDE; SONIC HEDGEHOG PROTEIN; SONIDEGIB; SURVIVIN; BIPHENYL DERIVATIVE; BIRC5 PROTEIN, MOUSE; IL2RG PROTEIN, MOUSE; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 2 RECEPTOR GAMMA; KI 67 ANTIGEN; NAPHTHOQUINONE; PYRIDINE DERIVATIVE; REPRESSOR PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; G2 PHASE CELL CYCLE CHECKPOINT; GENE DELETION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT DURATION; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CYCLE; CEREBELLAR NEOPLASMS; CHEMORADIOTHERAPY; CHILD; CONFOCAL MICROSCOPY; DEFICIENCY; DRUG EFFECTS; DRUG SCREENING; GENETICS; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; NUDE MOUSE; RADIATION RESPONSE; SCID MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ERINACEIDAE; MURINAE; MUS;

ANIMALS; APOPTOSIS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; CHEMORADIOTHERAPY; CHILD; HEDGEHOG PROTEINS; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; KI-67 ANTIGEN; MEDULLOBLASTOMA; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, NUDE; MICE, SCID; MICROSCOPY, CONFOCAL; NAPHTHOQUINONES; PYRIDINES; REPRESSOR PROTEINS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937522513     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.304     Document Type: Article

References (68)

1. Packer RJ, Cogen P, Vezina G, Rorke LB. Medulloblastoma: clinical and biologic aspects. Neuro-Oncology 1999; 1: 232-250.
2. Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol 2008; 65: 1419-1424.
3. Fossati P, Ricardi U, Orecchia R. Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy. Cancer Treat Rev 2009; 35: 79-96.
4. Northcott PA, Dubuc AM, Pfister S, Taylor MD. Molecular subgroups of medulloblastoma. Expert Rev Neurotherap 2012; 12: 871-884.
5. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361: 1173-1178.
6. Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 2013; 19: 1410-1422.
7. Kool M, Jones DT, Jager N, Northcott PA, Pugh TJ, Hovestadt V et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 2014; 25: 393-405.
8. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
9. Wheatley SP, McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 2005; 247: 35-88.
10. Huang LN, Wang DS, Chen YQ, Zhao CL, Gong BL, Jiang AB et al. Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies. Mol Biol Rep 2013; 40: 917-924.
11. Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S et al. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 2007; 27: 2803-2808.
12. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L et al. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 2011; 118: 2191-2199.
13. Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000; 111: 196-203.
14. Fangusaro JR, Caldas H, Jiang Y, Altura RA. Survivin: an inhibitor of apoptosis in pediatric cancer. Pediatr Blood Cancer 2006; 47: 4-13.
15. Shirai K, Suzuki Y, Oka K, Noda SE, Katoh H, Itoh J et al. Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neuro-Oncol 2009; 91: 353-358.
16. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998; 152: 43-49.
17. Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P, Patel BK. Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Therap 2011; 10: 221-232.
18. Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS ONE 2012; 7: e45571.
19. Nagaraj S, Pisarev V, Kinarsky L, Sherman S, Muro-Cacho C, Altieri DC et al. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother 2007; 30: 169-179.
20. Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I et al. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anti-cancer Drugs 2011; 22: 454-462.
21. Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA et al. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine 2007; 25: 7955-7961.
22. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castrationresistant taxane-pretreated prostate cancer. Ann Oncol 2012; 23: 968-973.
23. Becker JC, Andersen MH, Hofmeister-Muller V, Wobser M, Frey L, Sandig C et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother 2012; 61: 2091-2103.
24. Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J et al. A multicenter phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest N Drugs 2011; 29: 161-166.
25. Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 68: 505-511.
26. Talbot DC, Ranson M, Davies J, Lahn M, Callies S, Andre V et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 2010; 16: 6150-6158.
27. Haberler C, Slavc I, Czech T, Gelpi E, Heinzl H, Budka H et al. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. Eur J Cancer 2006; 42: 2996-3003.
28. Fangusaro JR, Jiang Y, Holloway MP, Caldas H, Singh V, Boue DR et al. Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 2005; 92: 359-365.
29. Li XN, Shu Q, Su JM, Adesina AM, Wong KK, Perlaky L et al. Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol 2007; 33: 67-76.
30. Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulas M et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008; 14: 135-145.
31. Xing Z, Conway EM, Kang C, Winoto A. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 2004; 199: 69-80.
32. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021.
33. Berezov A, Cai Z, Freudenberg JA, Zhang H, Cheng X, Thompson T et al. Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin. Oncogene 2012; 31: 1938-1948.
34. Guvenc H, Pavlyukov MS, Joshi K, Kurt H, Banasavadi-Siddegowda YK, Mao P et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res 2013; 19: 631-642.
35. Blomstrand M, Brodin NP, Munck Af Rosenschold P, Vogelius IR, Sanchez Merino G, Kiil-Berthlesen A et al. Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma. Neuro-Oncology 2012; 14: 882-889.
36. Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 2005; 23: 5511-5519.
37. Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008; 14: 6496-6504.
38. Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett 2010; 1: 130-134.
39. Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 2014; 20: 1900-1909.
40. Markant SL, Esparza LA, Sun J, Barton KL, McCoig LM, Grant GA et al. Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. Cancer Res 2013; 73: 6310-6322.
41. Zhao X, Liu Z, Yu L, Zhang Y, Baxter P, Voicu H et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro-Oncology 2012; 14: 574-583.
42. Minematsu T, Sonoda T, Hashimoto T, Iwai M, Oppeneer T, Felder L et al. Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats. Biopharm Drug Dispos 2012; 33: 160-169.
43. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 2011; 102: 614-621.
44. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007; 8: 798-812.
45. Yue Z, Carvalho A, Xu Z, Yuan X, Cardinale S, Ribeiro S et al. Deconstructing Survivin: comprehensive genetic analysis of Survivin function by conditional knockout in a vertebrate cell line. J Cell Biol 2008; 183: 279-296.
46. Saito T, Hama S, Izumi H, Yamasaki F, Kajiwara Y, Matsuura S et al. Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells. Br J Cancer 2008; 98: 345-355.
47. Rosa J, Canovas P, Islam A, Altieri DC, Doxsey SJ. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell 2006; 17: 1483-1493.
48. Arora R, Shuda M, Guastafierro A, Feng H, Toptan T, Tolstov Y et al. Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med 2012; 4: 133ra56.
49. Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M et al. Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem Biophys Res Commun 2012; 425: 711-716.
50. Nakamura N, Yamauchi T, Hiramoto M, Yuri M, Naito M, Takeuchi M et al. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin. Mol Cell Proteom 2012; 11: M111 013243.
51. Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A et al. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol 2012; 3: 179-197.
52. Tao YF, Lu J, Du XJ, Sun LC, Zhao X, Peng L et al. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer 2012; 12: 619.
53. Grinstein E, Jundt F, Weinert I, Wernet P, Royer HD. Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene 2002; 21: 1485-1492.
54. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004; 23: 7494-7506.
55. Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia 2012; 26: 271-279.
56. Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, Kiyonaga F et al. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res 2011; 17: 5423-5431.
57. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60: 2805-2809.
58. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metast Rev 2001; 20: 3-11.
59. Rodel F, Frey B, Leitmann W, Capalbo G, Weiss C, Rodel C. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 2008; 71: 247-255.
60. Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A et al. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin. Mol Cancer Therap 2012; 11: 204-213.
61. Hall WA, Sherr GT. Convection-enhanced delivery of targeted toxins for malignant glioma. Expert Opin Drug Deliv 2006; 3: 371-377.
62. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007; 25: 837-844.
63. Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 1996; 2: 963-972.
64. Serwer LP, James CD. Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations. Adv Drug Deliv Rev 2012; 64: 590-597.
65. Ellis T, Smyth I, Riley E, Graham S, Elliot K, Narang M et al. Patched 1 conditional null allele in mice. Genesis 2003; 36: 158-161.
66. Machold R, Fishell G. Math1 is expressed in temporally discrete pools of cerebellar rhombic-lip neural progenitors. Neuron 2005; 48: 17-24.
67. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277: 1109-1113.
68. Oliver TG, Read TA, Kessler JD, Mehmeti A, Wells JF, Huynh TT et al. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development 2005; 132: 2425-2439.